BioWisdom Announces Release of Safety Intelligence Program Version 3.0
BioWisdom Ltd (BioWisdom), a market leader in delivering healthcare intelligence to the pharmaceutical industry, today announced that it has released of Version 3 of its award-winning Safety Intelligence Program.
The Safety Intelligence Program is a unique system in providing comprehensive intelligence around compounds causing adverse effects in tissues, and enables in-depth understanding of mechanistic relationships drug-induced pathologies.
Version 3 provides new visualizations to provide immediate insight on compounds and their tissue effects, for scientists who need to understand the mechanisms of drug-induced adverse events and assess liability of drug candidates. Furthermore, it provides fully-searchable FDA New Drug Applications (NDAs) and allows users to search for information across categories of drugs, proteins, and pathologies.
“This latest version responds to the requests of the growing body of pharmaceutical scientists now using the Safety Intelligence Program. Users can now make complex interrogations of the assertional data contained in the Program, and through an interactive and visual dashboard, be rapidly taken to summary data that may have parallels to their own drug program. This not only saves them an enormous amount of time but it also empowers answers to questions that otherwise could not be addressed” said Jane Reed, Safety Intelligence Program Product Manager, BioWisdom.
Scientists use the Safety Intelligence Program to support investigative toxicology in understanding mechanisms of liability, to assess chemical structure for potential risk, to support project teams in their decision-making in relation to the safety profile of their lead candidates, and to provide insight into the development of new non-clinical models for drug safety assessment.
Tags: Intelligence, safety, SIP, toxicology